Innovative Research
The innovative CRO company specialized in high-end in vitro models of neurodegenerative diseases and drug development
EVENTS
25 AVR. 2019 : New publication released
Check out our new Parkinson’s disease paper published in PLOS ONE : Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins.
Our study depicts the cell death mechanisms taking place in in vitro models of Parkinson’s disease and how mitochondrial dysfunctions is at the cross road of the pathologies of this disease.
> Article
July 2019 Press Release
Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications
> Link to PR
19/09/2019 : NEURO-SYS AWARDED BEST INTERNATIONAL DRUG DEVELOPMENT AND DISCOVERY DEVELOPMENT COMPANY FOR 2019 BY GHP !
GHP has identified and rewarded Neuro-Sys for the quality of its scientific work on neurodegenerative diseases and the quality of the studies carried out with its customers (pharmaceutical laboratories, biotech...).
This is a tremendous recognition of the work done by the Neuro-Sys team and for its development.
> Link to the article about Neuro-Sys.
> Link to the GHP issue.
Check out our new poster
Impairment of lysosomal activity contributes to synucleinopathy and neurodegeneration in in vitro models of Parkinson’s disease.
> Poster
Check out our new poster
Acute and chronic dopaminergic neurotoxicity of alpha-synuclein oligomers : two distinct mechanisms.
> Poster
NEURO-SYS @ SFN 2019
Our management team will attend the Society For Neuroscience 2019 meeting.
Let’s take this opportunity to meet each other !
Preclinical services
Neuro-Sys has developed specific preclinical in vitro models of CNS and PNS diseases to achieve high-quality efficacy pharmacology as well as mode of action studies, a unique cost-effective strategy to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action. We provide studies to determine the neuroprotective activity of lead compounds but also of dietary supplements and medical nutrition.
We are dedicated to providing high-level technical expertise and preclinical CRO services in a collaborative relationship with our clients, mainly focusing on :
› Alzheimer’s disease (AD)
› Parkinson’s disease (PD)
› Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease)
› Multiple Sclerosis (MS)
› Peripheral Neuropathies
NEURO-SYS HAS BEEN AWARDED "BEST INTERNATIONAL DRUG DEVELOPMENT AND DISCOVERY DEVELOPMENT COMPANY, 2019" BY GHP !
(SPE)
(natural or chemical source)
Drug discovery
Neuro-Sys is developing a pipeline of innovative compounds focused on treatments for neurodegenerative diseases, orphan diseases and auto-immune diseases, both internally and through collaborations. We identify our lead compounds using our innovative and cutting-edge technology platform, including our internal manufacturing process.
13120 GARDANNE - FRANCE
info@neuro-sys.com
+33 (0)4 13 41 51 71
+33 (0)4 13 41 51 72
BOSTON MA 02109 - USA
info@neuro-sys.com
+1 617-588-3257